


### Adjusted Mean Change From Baseline To The End Of Study For Individual symptom Score

Protocol: Emetisol Nasal Spray  
Graph 3.9

Adjusted Mean Change from Baseline to the End of Study for Individual Symptom Score  
(Intent-to-Treat)



\* Baseline total symptom score and study center adjusted mean change

FIG. 1

Mean (Linear) 0-4h Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 1

Mean  
Day 1




FIG. 2A

Mean (Linear) 0-4h Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 1

Mean  
Day 1




FIG. 2B

Mean (Linear) 0-4h Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 1




FIG. 2C

Mean (Linear) Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 1





FIG. 3A

Mean (Linear) Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 1

Mean  
Day 1



■ Treatment B (10mg METO Nasal Spray)

FIG. 3B

Mean (Linear) Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 1

Mean  
Day 1




FIG. 3C

Mean (Linear) Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 42

Mean  
Day 42




FIG. 4A



Mean (Linear) Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 42

Mean  
Day 42




FIG. 4B

Mean (Linear) Metoclopramide Plasma Concentration-Time Profiles following a Single Oral or Nasal Spray Dose, Study Day 42

Mean  
Day 42




FIG. 4C